Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
87245470 |
LAW OFFICE ASSIGNED |
LAW OFFICE 109 |
MARK SECTION |
MARK |
http://uspto.report/TM/87245470/mark.png |
LITERAL ELEMENT |
IMCORE |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
MARK STATEMENT |
The mark consists of standard characters, without claim to any particular font style, size or color. |
EVIDENCE SECTION |
EVIDENCE FILE NAME(S) |
ORIGINAL PDF FILE |
evi_65175310-20171020171132951790_._Office_Action_Response_-_IMCORE.pdf |
CONVERTED PDF FILE(S)
(1 page) |
\\TICRS\EXPORT17\IMAGEOUT17\872\454\87245470\xml11\ROA0002.JPG |
DESCRIPTION OF EVIDENCE FILE |
evidence addressing the prior-filed application |
GOODS AND/OR SERVICES SECTION (current) |
INTERNATIONAL CLASS |
042 |
DESCRIPTION |
Identifying approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches,
to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (proposed) |
INTERNATIONAL CLASS |
042 |
TRACKED TEXT DESCRIPTION |
Identifying approaches to extend the benefit of cancer immunotherapy to patients and collaborate to
identify new treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy; Research and development of advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new
treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy |
FINAL DESCRIPTION |
Research and development of advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer
immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer
immunotherapy |
FILING BASIS |
Section 1(b) |
SIGNATURE SECTION |
RESPONSE SIGNATURE |
/shameek ghose/ |
SIGNATORY'S NAME |
shameek ghose |
SIGNATORY'S POSITION |
Sr. IP Counsel |
DATE SIGNED |
10/20/2017 |
AUTHORIZED SIGNATORY |
YES |
FILING INFORMATION SECTION |
SUBMIT DATE |
Fri Oct 20 17:59:00 EDT 2017 |
TEAS STAMP |
USPTO/ROA-XX.XXX.X.XX-201
71020175900769047-8724547
0-51076b90cf424b1676ebc66
1f992f5b355bfeb486d3d2a4e
7cbf5c93f1f75f1765-N/A-N/
A-20171020171132951790 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
To the Commissioner for Trademarks:
Application serial no.
87245470 IMCORE(Standard Characters, see http://uspto.report/TM/87245470/mark.png) has been amended as follows:
EVIDENCE
Evidence in the nature of evidence addressing the prior-filed application has been attached.
Original PDF file:
evi_65175310-20171020171132951790_._Office_Action_Response_-_IMCORE.pdf
Converted PDF file(s) ( 1 page)
Evidence-1
CLASSIFICATION AND LISTING OF GOODS/SERVICES
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 042 for Identifying approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical
trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Identifying approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches,
to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy;
Research and development of
advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly
initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapyClass 042 for Research and development of advanced learning technologies and
teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical trials and to
aggregate and share data to accelerate progress in the field of cancer immunotherapy
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
SIGNATURE(S)
Response Signature
Signature: /shameek ghose/ Date: 10/20/2017
Signatory's Name: shameek ghose
Signatory's Position: Sr. IP Counsel
The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which includes the District of Columbia, Puerto Rico, and
other federal territories and possessions; and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another
U.S. attorney or a Canadian attorney/agent not currently associated with his/her company/firm previously represented the owner/holder in this matter: (1) the owner/holder has filed or is concurrently
filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior representative to withdraw; (3) the owner/holder has filed a power of
attorney appointing him/her in this matter; or (4) the owner's/holder's appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in
this matter.
Serial Number: 87245470
Internet Transmission Date: Fri Oct 20 17:59:00 EDT 2017
TEAS Stamp: USPTO/ROA-XX.XXX.X.XX-201710201759007690
47-87245470-51076b90cf424b1676ebc661f992
f5b355bfeb486d3d2a4e7cbf5c93f1f75f1765-N
/A-N/A-20171020171132951790